



Fungal Testing Overview

Fungal antigens, fungal DNA, and anti-fungal antibodies can be used as non-invasive biomarkers for invasive fungal infections (IFIs). MiraVista Diagnostics (MVD) specializes in developing diagnostic tests to detect these biomarkers. These tests provide a rapid, cost-efficient alternative to invasive testing, often required otherwise to diagnose IFIs. Over the past 20 years MVD tests have revolutionized diagnosis and treatment monitoring of IFIs in animals. Use has been reported in many peer-reviewed publications. The reported diagnostic performances are found below.

Diagnostic performance of MVD fungal tests. **Bolded tests** are the recommended first non-invasive diagnostic test(s) to be performed.

Pathogen	Test	Species	Sample	Sensitivity	Specificity#	Min. Vol. (ml)^	Test Code	Ref.
Blastomyces*	Antigen EIA	К9	Urine	93	98	0.5	316	1-4
		K9	Serum	91	100	0.8	316	2,3,5
	Antibody EIA	K9	Serum	82	97	0.25	330	2,3
	Antibody ID	K9	Serum	54	100	0.25	322	2,3,6,7
Histoplasma	Antigen EIA	K9	Urine	92	99	0.5	310	8,9
		Feline	Urine	94	98	0.5	310	10,11
		Feline	Serum	73	NA	0.8	310	12
	Antibody EIA	K9	Serum	76	93	0.25	327	MVD
		Feline	Serum	83	95	0.25	328	MVD
	Antibody ID	K9	Serum	28	100	0.25	321	MVD
		Feline	Serum	5	100	0.25	321	MVD
<i>Coccidioides</i> (valley fever)	Antigen EIA	K9	Urine	8	100	0.5	315	13,14
		K9	Serum	27	97	0.8	315	13,14
	Antibody EIA	K9	Serum	89	94	0.25	329	13
	Antibody ID	K9	Serum	87	92	0.25	320	13,15,16
		Feline	Serum	99	NA	0.25	320	17,18
	Antibody ID+EIA	K9	Serum	99	95	0.5	329+320	13
Cryptococcus	Antigen LA	К9	Serum	91	100	0.25	319	19-21
		Feline	Serum	98	NA	0.25	319	19,21,22
<i>Aspergillus</i> (systemic)	Antigen EIA	K9	Urine	88	92	0.8	309	23
		K9	Serum	92	84	0.8	309	23
		K9	Ur+Ser	100	84-92	0.8	309	23
Aspergillus (sinonasal)	Antigen EIA	K9	Serum	24	82	0.8	309	24
		Feline	Serum	23	78	0.8	309	25
	Antibody ID	K9	Serum	76	100	0.25	324	24
		Feline	Serum	43	100	0.25	324	26


For tests with multiple references the combined sensitivity and specificity was provided.

*Blastomyces antigen test on urine is also the first-choice test for cats.

^Minimum sample volume required for testing.

#Specificity was often provided for non-fungal disease.


EIA, enzyme immunoassay; ID, immunodiffusion; LA, latex agglutination







Geographic location of enzootic invasive fungal infections (IFIs) is an important consideration. Cryptococcosis and aspergillosis, along with other invasive molds, occur anywhere in the U.S. Although infections can occur sporadically anywhere, IFIs due to dimorphic fungi (*Blastomyces, Histoplasma*, and *Coccidioides*) are found more commonly in predictable locations. The map below provides a rough estimate of enzootic regions.





Version 1 | May 2021





Invasive fungal infections (IFIs) commonly include non-specific findings such as lethargy, anorexia, weight loss, and fever unresponsive to antibiotics. Other more specific findings are also often present and can help guide diagnostic testing. Any IFI can affect any single organ or be multi-systemic, but patterns exist.

Common anatomic locations and clinical signs of invasive fungal infections in dogs and cats.


PATHOGEN	SPECIES AFFECTED	COMMON ORGANS INVOLVED	COMMON CLINICAL SIGNS
Blastomyces	Dog>>>Cat	Lung Lymph nodes Skin Eyes/periocular tissues Bones/joints Testicles/prostate (dog)	Anorexia Weight loss Fever Tachypnea Cough Lameness Vision disturbance Cutaneous Lesions
Histoplasma	Cat>Dog	Lung Lymph node Spleen & Liver Eyes/periocular tissues Bone marrow Bone/joints (cat) GI tract (dog)	Anorexia Weight loss Fever Tachypnea Lameness Vision disturbance Cutaneous lesions Diarrhea
Cryptococcus	Cat>>>Dog	Nasal cavity & sinuses Eyes & periocular tissues Lymph nodes Skin CNS Abdominal viscera (dog)	Nasal discharge Facial deformity Cutaneous lesions Blindness CNS signs Vomiting, diarrhea (dog)
Coccidioides (valley fever)	Dog>>Cat	Lung Lymph nodes Skin Eyes CNS Bones/joints	Anorexia Weight loss Tachypnea Cough Lameness Cutaneous lesions CNS signs
<i>Aspergillus</i> (systemic)	Dog>>>Cat	Bone/joints Vertebral end plates CNS Kidney Lymph nodes Skin Eyes Abdominal viscera	Anorexia Weight loss Fever Lameness Vision disturbance CNS signs Cutaneous lesions PU/PD
<i>Aspergillus</i> (sinonasal)	Dog>>Cat	Nasal cavity Sinuses Orbit CNS	Nasal discharge Nasal depigmentation Facial deformity CNS signs





With many available tests, choosing the best test can be challenging. In some cases, a combination of tests for a specific pathogen is preferred. For others, sequential testing might be needed. Considering the overlap of clinical findings, and enzootic areas, testing for multiple fungal pathogens is appropriate in many cases. To help simplify test selection, and treatment considerations, algorithms are provided below.

Diagnostic and Treatment Algorithm for Blastomycosis in Dogs or Cats



Antibody EIA test is not available for cats and Antibody ID test would be used instead.

*Monitor urine antigen unless above the limit of quantification then monitor serum until urine antigen concentration is quantifiable.


^Mild-moderate disease could be defined as disease which can be treated on an out-patient basis and life-threatening disease requires hospitalization.

HEADQUARTERS 4705 Decatur Blvd. | Indianapolis, Indiana 46241, USA





Diagnostic and Treatment Algorithm for Histoplasmosis in Dogs or Cats



*Monitor urine antigen unless above the limit of quantification then monitor serum until urine antigen concentration is quantifiable.


^Mild-moderate disease could be defined as disease which can be treated on an out-patient basis and life-threatening disease requires hospitalization.



Version 1 | May 2021



Diagnostic and Treatment Algorithm for Coccidioidomycosis (Valley Fever) in Dogs or Cats



Antibody EIA test is not available for cats and Antibody ID test would be used as the sole initial screening test.

#Use antigen test for treatment monitoring if positive at baseline. If not use antibody tests for monitoring.

^Mild-moderate disease could be defined as disease which can be treated on an out-patient basis and life-threatening disease requires hospitalization. *Fluconazole is the most commonly used oral treatment, but in vitro sensitivity data and clinical data from human medicine suggests that itraconazole should be considered as first-line treatment.


HEADQUARTERS 4705 Decatur Blvd. | Indianapolis, Indiana 46241, USA




Version 1 | May 2021



Diagnostic and Treatment Algorithm for Cryptococcosis in Dogs or Cats




^Mild-moderate disease could be defined as disease which can be treated on an out-patient basis and life-threatening disease requires hospitalization.



Version 1 | May 2021



Diagnostic and Treatment Algorithm for Systemic Aspergillosis in Dogs or Cats



*Use whichever sample had the highest initial antigen concentration for treatment monitoring.

^Mild-moderate disease could be defined as disease which can be treated on an out-patient basis and life-threatening disease requires hospitalization.






Version 1 | May 2021



Diagnostic and Treatment Algorithm for Sinonasal Aspergillosis in Dogs or Cats





Version 1 | May 2021





- Motschenbacher LO, Furrow E, Rendahl AK, et al. Retrospective analysis of the effects of *Blastomyces* antigen concentration in urine and radiographic findings on survival in dogs with blastomycosis. J Vet Intern Med 2021.
- Mourning AC, Patterson EE, Kirsch EJ, et al. Evaluation of an enzyme immunoassay for antibodies to a recombinant *Blastomyces* adhesin-1 repeat antigen as an aid in the diagnosis of blastomycosis in dogs. J Am Vet Med Assoc 2015;247:1133-1138.
- Spector D, Legendre AM, Wheat J, et al. Antigen and antibody testing for the diagnosis of blastomycosis in dogs. J Vet Intern Med 2008;22:839-843.
- Foy DS, Trepanier LA, Kirsch EJ, et al. Serum and urine *Blastomyces* antigen concentrations as markers of clinical remission in dogs treated for systemic blastomycosis. J Vet Intern Med 2014;28:305-310.
- Arambulo PV, 3rd, Topacio TM, Jr., Famatiga EG, et al. Leptospirosis among abattoir employees, dog pound workers, and fish inspectors in the city of Manila. The Southeast Asian journal of tropical medicine and public health 1972;3:212-220.
- Arceneaux KA, Taboada J, Hosgood G. Blastomycosis in dogs: 115 cases (1980-1995). J Am Vet Med Assoc 1998;213:658-664.
- Crews LJ, Feeney DA, Jessen CR, et al. Utility of diagnostic tests for and medical treatment of pulmonary blastomycosis in dogs: 125 cases (1989-2006). J Am Vet Med Assoc 2008;232:222-227.
- Cunningham L, Cook A, Hanzlicek A, et al. Sensitivity and Specificity of Histoplasma Antigen Detection by Enzyme Immunoassay. J Am Anim Hosp Assoc 2015;51:306-310.
- Clark K, Hanzlicek AS. Evaluation of a novel monoclonal antibody-based enzyme immunoassay for detection of *Histoplasma* antigen in urine of dogs. J Vet Intern Med 2020.
- Cook AK, Cunningham LY, Cowell AK, et al. Clinical evaluation of urine Histoplasma capsulatum antigen measurement in cats with suspected disseminated histoplasmosis. J Feline Med Surg 2012;14:512-515.
- Rothenburg L, Hanzlicek AS, Payton ME. A monoclonal antibody-based urine *Histoplasma* antigen enzyme immunoassay (IMMY(R)) for the diagnosis of histoplasmosis in cats. J Vet Intern Med 2019;33:603-610.
- Hanzlicek AS, Meinkoth JH, Renschler JS, et al. Antigen Concentrations as an Indicator of Clinical Remission and Disease Relapse in Cats with Histoplasmosis. J Vet Intern Med 2016;30:1065-1073.
- Holbrook ED, Greene RT, Rubin SI, et al. Novel canine anti-Coccidioides immunoglobulin G enzyme immunoassay aids in diagnosis of coccidioidomycosis in dogs. Medical mycology 2019;57:800-806.

- Kirsch EJ, Greene RT, Prahl A, et al. Evaluation of *Coccidioides* antigen detection in dogs with coccidioidomycosis. Clin Vaccine Immunol 2012;19:343-345.
- Johnson LR, Herrgesell EJ, Davidson AP, et al. Clinical, clinicopathologic, and radiographic findings in dogs with coccidioidomycosis: 24 cases (1995-2000). J Am Vet Med Assoc 2003;222:461-466.
- Gunstra A, Steurer JA, Seibert RL, et al. Sensitivity of Serologic Testing for Dogs Diagnosed with Coccidioidomycosis on Histology: 52 Cases (2012-2013). J Am Anim Hosp Assoc 2019;55:238-242.
- Arbona N, Butkiewicz CD, Keyes M, et al. Clinical features of cats diagnosed with coccidioidomycosis in Arizona, 2004-2018. J Feline Med Surg 2020;22:129-137.
- Greene RT, Troy GC. Coccidioidomycosis in 48 cats: a retrospective study (1984-1993). J Vet Intern Med 1995;9:86-91.
- Malik R, McPetrie R, Wigney DI, et al. A latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosis. Aust Vet J 1996;74:358-364.
- Johnston L, Mackay B, King T, et al. Abdominal cryptococcosis in dogs and cats: 38 cases (2000-2018). J Small Anim Pract 2021;62:19-27.
- Trivedi SR, Sykes JE, Cannon MS, et al. Clinical features and epidemiology of cryptococcosis in cats and dogs in California: 93 cases (1988-2010). J Am Vet Med Assoc 2011;239:357-369.
- Medleau L, Marks MA, Brown J, et al. Clinical evaluation of a cryptococcal antigen latex agglutination test for diagnosis of cryptococcosis in cats. J Am Vet Med Assoc 1990;196:1470-1473.
- Garcia RS, Wheat LJ, Cook AK, et al. Sensitivity and specificity of a blood and urine galactomannan antigen assay for diagnosis of systemic aspergillosis in dogs. J Vet Intern Med 2012;26:911-919.
- Billen F, Peeters D, Peters IR, et al. Comparison of the value of measurement of serum galactomannan and Aspergillus-specific antibodies in the diagnosis of canine sino-nasal aspergillosis. Vet Microbiol 2009;133:358-365.
- Whitney J, Beatty JA, Martin P, et al. Evaluation of serum galactomannan detection for diagnosis of feline upper respiratory tract aspergillosis. Vet Microbiol 2013;162:180-185.
- Barrs VR, Ujvari B, Dhand NK, et al. Detection of Aspergillus-specific antibodies by agar gel double immunodiffusion and IgG ELISA in feline upper respiratory tract aspergillosis. Vet J 2015;203:285-289.

HEADQUARTERS 4705 Decatur Blvd. | Indianapolis, Indiana 46241, USA

888-841-8387

Version 1 | May 2021